These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 37838564)

  • 1. Leukapheresis for CAR-T cell production and therapy.
    Pessach I; Nagler A
    Transfus Apher Sci; 2023 Dec; 62(6):103828. PubMed ID: 37838564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture.
    Tyagarajan S; Schmitt D; Acker C; Rutjens E
    Cytotherapy; 2019 Dec; 21(12):1198-1205. PubMed ID: 31837735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing.
    Qayed M; McGuirk JP; Myers GD; Parameswaran V; Waller EK; Holman P; Rodrigues M; Clough LF; Willert J
    Cytotherapy; 2022 Sep; 24(9):869-878. PubMed ID: 35718701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haematology laboratory parameters to assess efficacy of CD19-, CD22-, CD33-, and CD123-directed chimeric antigen receptor T-cell therapy in haematological malignancies.
    Drumheller B; Gebre K; Lockhart B; Margolskee E; Obstfeld A; Paessler M; Pillai V
    Int J Lab Hematol; 2022 Aug; 44(4):750-758. PubMed ID: 35419923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
    Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
    Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [How to perform leukapheresis for procurement of the staring material used for commercial CAR T-cell manufacturing: A consensus from experts convened by the SFGM-TC].
    Carnoy S; Beaumont JL; Kanouni T; Parquet N; Beauvais D; Hequet O; Kanold J; Ballot C; Mialou V; Reppel L; Damaj G; Yakoub-Agha I; Chabannon C
    Bull Cancer; 2021 Mar; 108(3):295-303. PubMed ID: 33610284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advantages of high cell concentration prior to cryopreservation of initial leukapheresis in CAR-T cell therapy.
    Carbonell D; Monsalvo S; Catalá E; Pérez-Corral A; Villegas C; Falero C; Ruano G; Martinez M; Kwon M; Muñoz-Martínez C; Díez-Martín JL; Gayoso J; Anguita J
    Blood Transfus; 2024 May; 22(3):239-245. PubMed ID: 38063787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
    Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
    BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
    Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
    Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
    Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Building blocks for institutional preparation of CTL019 delivery.
    McGuirk J; Waller EK; Qayed M; Abhyankar S; Ericson S; Holman P; Keir C; Myers GD
    Cytotherapy; 2017 Sep; 19(9):1015-1024. PubMed ID: 28754600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
    Lee DW; Kochenderfer JN; Stetler-Stevenson M; Cui YK; Delbrook C; Feldman SA; Fry TJ; Orentas R; Sabatino M; Shah NN; Steinberg SM; Stroncek D; Tschernia N; Yuan C; Zhang H; Zhang L; Rosenberg SA; Wayne AS; Mackall CL
    Lancet; 2015 Feb; 385(9967):517-528. PubMed ID: 25319501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
    Teoh J; Brown LF
    Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
    Schubert ML; Dietrich S; Stilgenbauer S; Schmitt A; Pavel P; Kunz A; Bondong A; Wegner M; Stadtherr P; Jung S; Ho AD; Müller-Tidow C; Schmitt M; Dreger P
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):1575-1580. PubMed ID: 32422254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia.
    Xie L; Ma L; Liu S; Chang L; Wen F
    Int Immunopharmacol; 2021 Jul; 96():107731. PubMed ID: 33965880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cryopreserved leukapheresis material can be transferred from controlled rate freezers to ultracold storage at warmer temperatures without affecting downstream CAR-T cell culture performance and in-vitro functionality.
    Wei J; Chaney K; Shim WJ; Chen H; Leonard G; O'Brien S; Liu Z; Jiang J; Ulrey R
    Cryobiology; 2024 Jun; 115():104889. PubMed ID: 38513998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report.
    Schultz L; Patel S; Davis KL; Ramakrishna S; Sahaf B; Bhatia N; Baggott C; Erickson C; Majzner RG; Oak J; Bertaina A; Mackall C; Feldman S
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32929049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
    George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
    BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL.
    Korell F; Laier S; Sauer S; Veelken K; Hennemann H; Schubert ML; Sauer T; Pavel P; Mueller-Tidow C; Dreger P; Schmitt M; Schmitt A
    Cells; 2020 May; 9(5):. PubMed ID: 32429189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.